Market Ignores Crude Spikes & US Inflation | Inside Sun Pharma’s Q2 Exceptional Loss..30-Oct-26

A stark divergence between resilient Indian equities and frail global macro cues defined Friday’s session. Even as fresh US inflation data and fears of US-Iran military escalations kept foreign markets defensive, the Nifty comfortably claimed the 23,050 zone. Tune into tonight's podcast as we dissect the reality behind Sun Pharma's 36.2% profit dip and evaluate the structural derivative support forming at the 23,000 baseline ahead of next week's trade. Get the facts here.